Ocugen (NASDAQ:OCGN) Price Target Increased to $5.00 by Analysts at Chardan Capital

Ocugen (NASDAQ:OCGN) had its price target raised by Chardan Capital from $4.00 to $5.00 in a research report sent to investors on Monday, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Ocugen in a research report on Wednesday, April 3rd.

Ocugen Stock Down 6.1 %

OCGN stock opened at $1.24 on Monday. The company’s 50 day simple moving average is $1.24 and its 200-day simple moving average is $0.74. The firm has a market capitalization of $319.09 million, a PE ratio of -4.59 and a beta of 3.51. Ocugen has a 12 month low of $0.35 and a 12 month high of $2.11. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.51 and a quick ratio of 2.51.

Institutional Trading of Ocugen

A hedge fund recently bought a new stake in Ocugen stock. David J Yvars Group bought a new position in shares of Ocugen, Inc. (NASDAQ:OCGN) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,170 shares of the company’s stock, valued at approximately $35,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.